Genprex’s Novel Immunogene Therapy in Lung Cancer Highlighted in Key Opinion Leader Event

Genprex’s lead drug candidate, REQORSA™ Immunogene Therapy that uses our proprietary, non-viral ONCOPREX® Nanoparticle Delivery System was highlighted in a Key Opinion Leader event hosted by Alliance Global Partners (AGP) for their institutional customers. 

The event, titled, Advances in Gene Therapy for Oncology: New Opportunities with REQORSA™ (TUSC2),” was moderated by James Molloy, Managing Director, Equity Research at AGP and featured discussions with experts Andrew Becker, M.D., Ph.D. and COL (ret) George Peoples, M.D., FACS.

The presentation gave an overview of REQORSA and ONCOPREX, including discussions suggesting that REQORSA could be the first systemic gene therapy used for cancer in humans. It also featured the large markets that REQORSA is addressing, as well as REQORSA and ONCOPREX’s potential to address a range of cancers. 

The discussion also reviewed highlights from Genprex’s two previous clinical trials, ONC-001, a REQORSA monotherapy clinical trial; and ONC-002, a combination of REQORSA and Roche’s Tarceva® in NSCLC. 

The KOLs also discussed the importance of the positive preclinical data presented in April at the 2021 American Association of Cancer Research (AACR) annual meeting that supported the use of REQORSA in combination with immunotherapies and with targeted therapies for the treatment of NSCLC.

On the Company’s Acclaim-1 and upcoming Acclaim-2 clinical trials:

“What I like about these trial designs is the potential to get added value and added time for patients out of Keytruda and Tagrisso, in order to delay the time before the patient has to begin a more toxic chemotherapy regimen,” said Dr. Becker. “The ability to continue on a PD-1 inhibitor or a targeted therapy longer, in patients that we know are tolerating it, is a benefit to the patient because it not only extends life, but it extends quality of life.”

On the positive preclinical data presented by our academic collaborators at the AACR annual meeting supporting REQORSA:

“These AACR studies are incredibly important because they are addressing the use of REQORSA in combination with what is the most current way we treat NSCLC patients clinically,” said Dr. Peoples. “What you will see with the AACR studies, is that Genprex is encompassing all of the patients in the first-line therapy setting, whether they have EGFR mutations and fall into the targeted therapy category, or if they are PD-L1 positive patients who will get pembrolizumab or a pembrolizumab combination with platinum chemotherapy. The data covers the majority of the first-line patients in these two AACR presentations.”

Learn more about the KOLs by reading Dr. Becker’s and Dr. Peoples’ bios. To watch the presentation in its entirety, a replay of the event can be found on the Genprex website. Since the KOL event recording on April 27, 2021, Genprex has initiated its Acclaim-1 clinical trial and has updated the Acclaim-2 protocol to include all late-stage NSCLC patients who have progressed after treatment with Keytruda, regardless of PD-L1 expression.

Cautionary Language Concerning Forward-Looking Statements 

Statements contained in this blog post regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex’s clinical trials and regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes;  Genprex’s future growth and financial status; Genprex’s commercial and strategic partnerships including the scale up of the manufacture of its product candidates; and Genprex’s intellectual property and licenses. 

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this blog post. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.